NanoViricides, Inc. NNVC 深 滬
已收盤 02-06 16:00:00 美东时间
0.88
+0.030
+3.53%
華盛通- 最 高0.93
- 今 開0.891
- 成交量 25.10万股
- 最 低 0.88
- 昨 收 0.85
- 總市值 1898.02万
- 52周最高 2.2299
- 市盈率 靜 --
- 換手率 1.16%
- 52周最低 0.85
- 委 比 0.00%
- 總股本 2156.84万
- 歷史最高 151.80
- 量 比 0.94
- 振 幅 5.88%
- 歷史最低 0.85
- 每 手 1
- 風險率 0.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NanoViricides President Unveils Breakthrough Antiviral Technology in Mission Matters Interview
NanoViricides President Unveils Breakthrough Antiviral Technology in Mission Matters Interview NanoViricides, Inc. President Dr. Anil R. Diwan was recently interviewed on the Mission Matters Podcast by Adam Torres. During the discussion, Dr. Diwan outlined the company's mission to revolutionize anti
02-02 21:32
NanoViricides Signs Master Services Agreement With Only Orphans Cote To Advance Orphan Drug Strategy For NV-387
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology
2025-12-01 21:35
NanoViricides Secures $6 Million Through Securities Offering
An update from NanoViricides ( ($NNVC) ) is now available. On November 10, 2025...
2025-11-15 06:13
NanoViricides Receives DRC Approval To Start Phase II Trial Of NV-387 For MPox Treatment
NanoViricides, Inc. (NYSE:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic
2025-11-10 21:35
Nanoviricides Q4 EPS $(0.13) Up From $(0.19) YoY
Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.13) per share. This is a 31.58 percent increase over losses of $(0.19) per share from the same period last year.
2025-09-30 05:55
NanoViricides shares are trading higher after the company announced it has been cleared by the DRC Ethics Committee to file a Phase II trial application for oral NV-387.
NanoViricides shares are trading higher after the company announced it has been...
2025-05-16 22:59
NanoViricides GAAP EPS of -$0.14
NanoViricides press release (NYSE:NNVC): Q3 GAAP EPS of -$0.14. More on NanoViricides Historical earnings data for NanoViricides Financial information for NanoViricides
2025-05-16 18:48
Nanoviricides Q3 GAAP EPS $(0.14) Up From $(0.16) YoY
Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.14) per share. This is a 12.5 percent increase over losses of $(0.16) per share from the same period last year.
2025-05-16 05:44
NanoViricides Secures CNES Approval For NV-387 Phase II Clinical Trial In Democratic Republic Of Congo
NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES) of the Ministry of Public Health (MSP), of the Democratic Republic
2025-05-08 18:39
